Phase 3 Clinical Trials With Primary Completion Dates in November 2018

This is a list of Phase 3 trials with primary completion dates in November 2018 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ALKS Alkermes plc 2018-11-01 Phase 3 NCT02694328 A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)
BYSI BeyondSpring, Inc. 2018-11-01 Phase 3 NCT02504489 Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC
CPRX Catalyst Pharmaceuticals, Inc. 2018-11-01 Phase 3 NCT02562066 Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes
ICLR ICON plc 2018-11-01 Phase 3 NCT02794168 Efficacy of VAS203 (Ronopterin) in Patients With Moderate and Severe Traumatic Brain Injury
IMGN ImmunoGen, Inc. 2018-11-01 Phase 3 NCT02631876 PH3 Study of Mirvetuximab Soravtansine vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer
PRAH PRA Health Sciences, Inc. 2018-11-01 Phase 3 NCT02817841 E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - US/CA Study
RDHL Redhill Biopharma Ltd. 2018-11-01 Phase 3 NCT03198507 ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator
VBIV VBI Vaccines, Inc. 2018-11-01 Phase 3 NCT03408730 Lot-to-lot Consistency of Sci-B-Vac™ in Adults
VSTM Verastem, Inc. 2018-11-01 Phase 3 NCT02049515 A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07